CTOs on the Move

Biohaven Pharmaceutical

www.biohavenpharma.com

 
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Biohaven Pharmaceutical raised $80M on 11/01/2016
Biohaven Pharmaceutical raised $80M on 07/03/2017
Biohaven Pharmaceutical raised $200M on 03/15/2021

Similar Companies

Nova Analytics Corporation

Nova Analytics Corporation is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

INmuneBIO

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.

DNA Script

DNA Script was created to revolutionize DNA synthesis with enzymes` Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation` The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology` With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine`

ChemBridge Research Laboratories (CRL)

ChemBridge Research Laboratories (CRL) is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tris Pharma

Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.